Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes

Conclusions IVIg did not reduce disability, improve strength, or quality of life in patients with demyelinating polyneuropathy features and diabetes after 3 months of treatment in comparison with placebo. Therefore, careful consideration of the primary diagnosis is required before immunomodulatory therapy. Classification of evidence This study provides Class I evidence that for patients with diabetes and demyelinating polyneuropathy features, IVIg did not significantly reduce disability.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Peripheral neuropathy, Chronic inflammatory demyelinating polyneuropathy, Clinical trials Randomized controlled (CONSORT agreement), Class I Article Source Type: research